Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 26 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $832.85, which forecasts a 11.86% increase in the stock price over the next year. The lowest target is $587 and the highest is $1,057.

Price Target: $832.85 (+11.86%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$587	$832.85	$850	$1,057
Change	-21.16%	+11.86%	+14.16%	+41.96%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	8	8	9	9	9	10
Buy	8	7	8	7	9	9
Hold	6	7	7	6	6	6
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	23	23	25	23	25	26

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tyler Van Buren TD Cowen	TD Cowen	Strong Buy Maintains $880 → $960	Strong Buy	Maintains	$880 → $960	+28.94%	Apr 23, 2026
Carter Gould Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $800	Buy	Reiterates	$800	+7.45%	Apr 23, 2026
Matthew Harrison Morgan Stanley	Morgan Stanley	Hold Maintains $769 → $796	Hold	Maintains	$769 → $796	+6.91%	Apr 10, 2026
William Pickering Bernstein	Bernstein	Buy Maintains $925 → $921	Buy	Maintains	$925 → $921	+23.70%	Apr 8, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Initiates $875	Buy	Initiates	$875	+17.52%	Mar 31, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

16.13B

Increased by 12.45%

from 14.34B

Revenue Next Year

17.76B

Increased by 10.13%

from 16.13B

EPS This Year

46.88

Increased by 13.02%

from 41.48

EPS Next Year

55.16

Increased by 17.67%

from 46.88

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	16.07B	12.17B	13.12B	14.20B	14.34B	16.13B	17.76B
Revenue Growth	89.14%	-24.26%	7.76%	8.27%	0.99%	12.45%	10.13%
EPS	71.97	38.22	34.77	38.34	41.48	46.88	55.16
EPS Growth	135.81%	-46.90%	-9.03%	10.27%	8.19%	13.02%	17.67%
Forward PE	-	-	-	-	-	15.88	13.50
No. Analysts	-	-	-	-	-	32	29

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	18.1B	20.0B
Avg	16.1B	17.8B
Low	14.4B	15.8B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	26.0%	23.9%
Avg	12.4%	10.1%
Low	0.3%	-2.3%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	60.51	65.84
Avg	46.88	55.16
Low	36.39	45.37

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	45.9%	40.4%
Avg	13.0%	17.7%
Low	-12.3%	-3.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.